Clinical Trials Logo

Vaccine Response Impaired clinical trials

View clinical trials related to Vaccine Response Impaired.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06262776 Not yet recruiting - Immunosuppression Clinical Trials

Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients

SIR ZOSTER
Start date: February 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between kidney transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in kidney transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between kidney transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.

NCT ID: NCT05923970 Not yet recruiting - Clinical trials for Vaccine Response Impaired

Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

Start date: September 1, 2024
Phase:
Study type: Observational

The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these viruses. The uncertainty of a woman's immune status is partly due to the type of testing that is used to indicate protection. While immunity to viral infection requires both a humoral and a cell mediated immune (CMI) response, only humoral (antibody) responses are measured routinely in the laboratory. This study will examine CMI responses and the role of a third dose of vaccine for previously vaccinated women whose antibody levels are below the cut off. This study will not administer vaccine, but rather will include women who have received a third dose of vaccination through routine health care follow up in the study cohort.